Fournier‘s gangrene and gliflozins in therapy of diabetes mellitus

Czech version

Authors: J. Brož ¹; J. Urbanová ²; L. Brunerová ²
Authors‘ workplace: Interní klinika FN Motol a 2. LF UK, Praha, přednosta prof. MUDr. M. Kvapil, CSc., MBA ¹; Centrum pro výzkum diabetu, metabolismu a výživy, II. interní klinika 3. LF UK a FNKV, Praha, přednosta prof. MUDr. M. Kršek, CSc. ²
Published in: Ceska Gynekol 2019; 84(1): 77
Category: Letters to the Editor

Sources

1. Lupsa, BC., Inzucchi, SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia, 2018, 61, p. 2118–2125. doi:10.1007/s00125-018-4663-6.

2. Sorensen, MD., Krieger, JN. Fournier‘s gangrene: epidemiology and outcomes in the general US population. Urol Int, 2016, 97(3), p. 249–259.

3. Šuráň, M., Jarošincová, J., Milota, J. Fournierova gangréna. Urol praxi, 2017, 18(3), p. 124–126.

4. The Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm [Accessed 01.12.2018].

5. Vasilakou, D., Karagiannis, T., Athanasiadou, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med, 2013, 159, p. 262–274.